Opaleye Management Inc. - 14 Jul 2022 Form 4 Insider Report for Tracon Pharmaceuticals, Inc.

Role
10%+ Owner
Signature
Opaleye Management Inc., By: /s/ James Silverman, President
Issuer symbol
N/A
Transactions as of
14 Jul 2022
Net transactions value
+$13,024
Form type
4
Filing time
14 Jul 2022, 18:25:57 UTC
Previous filing
05 Jul 2022
Next filing
15 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCON Common Stock, par value $0.001 per share Purchase $13,024 +7,187 +2.1% $1.81 355,920 14 Jul 2022 By Managed Account. F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TCON Prefunded Warrants 1,889,513 14 Jul 2022 Common Stock 1,889,513 $0.0100 By Opaleye,L.P. F3, F4
holding TCON Prefunded Warrants 1,358,593 14 Jul 2022 Common Stock 1,358,593 $0.0100 By Opaleye,L.P. F3, F4
holding TCON Prefunded Warrants 2,205,018 14 Jul 2022 Common Stock 2,205,018 $0.0100 By Opaleye,L.P. F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
F2 The common stock was purchased by the reporting person in open market transactions on the transaction date, with an average purchase price of $1.8122, and a range of $1.80-1.83. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased.
F3 Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F4 The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock.